Biomarkers of oxidative damage are elevated among individuals with high cardiovascular risk: Refining subject selection strategies for antioxidant trials

• Published in: Free radical research Vol. 47; no. 4; pp. 283 - 290
• Main Authors: Seet, Raymond C.S., Quek, Amy M.L., Lim, Erle C.H., Halliwell, Barry
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.04.2013; Taylor & Francis
• Subjects: Antioxidants - administration & dosage; atherosclerosis; biomarkers; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Clinical Trials as Topic; docosahexaenoic acid; F2-Isoprostanes - blood; gamma-Glutamyltransferase - blood; Humans; Hydroxycholesterols - blood; oxidative damage; Oxidative Stress; oxysterols; Precision Medicine; Risk Factors
• ISSN: 1071-5762; 1029-2470; 1029-2470
• DOI: 10.3109/10715762.2013.769215

Abstract The purpose of this study was to evaluate the use of Framingham risk scores (FRRs) to identify high-risk individuals with biochemical evidence of increased oxidative damage, who may benefit from antioxidant therapies. A bimodal change in plasma F2-isoprostane levels was observed with cardiovascular risk categories, while plasma neuroprostanes, 7α-hydroxycholesterol, and serum γ-glutamyltransferase levels were higher among individuals at high risk of cardiovascular events (Framingham score, > 36). Total plasma hydroxyeicosatetraenoic acid products (HETEs) and serum high-sensitivity CRP (hsCRP) levels were consistently higher across Framingham risk categories. Multivariable analysis identified plasma 7α-hydroxycholesterol (odds ratio (OR), 1.06; 95% confidence interval (CI), 1.03-1.10) and γ-glutamyltransferase (OR, 1.02; 95% CI, 1.01-1.03) as significant predictors of high cardiovascular risk (Framingham score, > 36), accounting for approximately 21% of its variation. Cardiovascular risk scores are useful to identify individuals with high burden of oxidative damage who may benefit from antioxidant therapy.